UPDATE 1-US surgeons perform first pig-to-human kidney transplant [Yahoo! Finance]
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: Yahoo! Finance
March 21 (Reuters) - A 62-year-man with end-stage renal disease has become the first human to receive a new kidney from a genetically modified pig, doctors from Massachusetts General Hospital in Boston announced on Thursday. The four-hour surgery, performed on March 16, “marks a major milestone in the quest to provide more readily available organs to patients,” the hospital said in a statement. The patient, Richard Slayman of Weymouth, Massachusetts, is recovering well and expected to be discharged soon, the hospital said. Slayman had received a transplant of a human kidney at the same hospital in 2018 after seven years on dialysis, but the organ failed after five years and he had resumed dialysis treatments. The kidney was provided by eGenesis of Cambridge, Massachusetts from a pig that had been genetically edited to remove genes that could be harmful to a human recipient and add certain human genes to improve compatibility. In addition, the company inactivated certain virus
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsGlobeNewswire
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionGlobeNewswire
- Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
ELDN
Earnings
- 11/9/23 - Beat
ELDN
Analyst Actions
- 3/22/24 - HC Wainwright
ELDN
Sec Filings
- 4/26/24 - Form 10-K/A
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- ELDN's page on the SEC website